This article reviews the evidence regarding clopidogrel and its impact on the treatment of acute coronary syndromes in contemporary practice.
Does clopidogrel improve outcomes in patients with acute coronary syndromes?
This article reviews the evidence for clopidogrel in the contemporary treatment of acute coronary syndromes.
Acute coronary syndromes (ACS) are the most common cause of death worldwide. In the United States, over 1,500,000 patients with an ACS are discharged annually (1). ACS is caused by disruption of an atherosclerotic plaque with superimposed thrombotic occlusion of the coronary artery, resulting in myocardial ischaemia or infarction. Platelets play a central role in the initiation and propagation of this process. As a result, effective anti-platelet therapy has become a cornerstone of ACS treatment. The objective of this article is to review the evidence regarding clopidogrel and its impact on the treatment of ACS in contemporary practice.
Bainey et al. (2011) conducted a review in Acute coronary syndromes (ACS). Clopidogrel was evaluated. This article reviews the evidence regarding clopidogrel and its impact on the treatment of acute coronary syndromes in contemporary practice.